stoxline Quote Chart Rank Option Currency Glossary
  
CERo Therapeutics Holdings, Inc. (CERO)
1.77  -0.11 (-5.85%)    02-19 15:58
Open: 1.86
High: 1.87
Volume: 141,728
  
Pre. Close: 1.88
Low: 1.74
Market Cap: 5(M)
Technical analysis
2025-02-19 3:20:30 PM
Short term     
Mid term     
Targets 6-month :  3.05 1-year :  3.71
Resists First :  2.61 Second :  3.18
Pivot price 1.94
Supports First :  1.7 Second :  1.41
MAs MA(5) :  1.87 MA(20) :  1.98
MA(100) :  8.6 MA(250) :  63.56
MACD MACD :  -0.8 Signal :  -1
%K %D K(14,3) :  15.7 D(3) :  14.2
RSI RSI(14): 35.3
52-week High :  1095 Low :  1.7
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CERO ] has closed above bottom band by 27.4%. Bollinger Bands are 95.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.02 - 2.03 2.03 - 2.04
Low: 1.83 - 1.84 1.84 - 1.85
Close: 1.86 - 1.88 1.88 - 1.9
Company Description

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Headline News

Thu, 06 Feb 2025
CERo Therapeutics Holdings, Inc. Highlights Progress - GlobeNewswire

Thu, 06 Feb 2025
CERo Therapeutics strengthens cash reserves, advances clinical trials - Investing.com

Thu, 06 Feb 2025
Major Cancer Treatment Breakthrough: CERo's Next-Gen Therapy Heads to Clinical Trials with Fresh Funding - StockTitan

Wed, 05 Feb 2025
CERo's Strategic $5M Capital Raise Draws Insider Investment - StockTitan

Wed, 05 Feb 2025
CERo Therapeutics Holdings, Inc. Announces Pricing of $5 Million Public Offering to Advance Innovative T Cell Immunotherapy Programs - Nasdaq

Tue, 07 Jan 2025
Cero Therapeutics to effect 1-for-100 reverse stock split - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 1 (M)
Held by Insiders 18.7 (%)
Held by Institutions 4.4 (%)
Shares Short 573 (K)
Shares Short P.Month 150 (K)
Stock Financials
EPS -118.56
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -4.95
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -87.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow 8 (M)
Stock Valuations
PE Ratio -0.02
PEG Ratio 0
Price to Book value -0.38
Price to Sales 0
Price to Cash Flow -0.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android